论文部分内容阅读
大剂量胸肽治疗类风湿性关炎的临床观察.结果发现胸腺肽对RA的疗效尚为满意.特总结报道如下:1 资料与方法1.1 临床资料 按美国风湿病协会1987年诊断标准.从1995年8月随机选定患者92例.其中男8例.女81例.年龄23岁～76岁.平均年龄19.6±12.9岁.病程11个月～28年.平均5.8±6.6年.作胸腺肽治疗前患者发病的x线分期.Ⅰ期18例.Ⅱ期25例.Ⅲ期13例.Ⅳ期6例.所有患者随机分为治疗组和对照组.治疗组48例,对照组44例.两组年龄,性别.病情无显著性差异.具有可比性.类风湿性关节炎(RA)是一种常见的慢性多关节破坏性疾病.在病程中容易出现骨关节的侵蚀、破坏.以致最后丧失功能,对病员的身心健康造成较大影响,目前国内外尚无特效的针对治疗方法.为此我院开展了应用
High-dose thymopeptide treatment of rheumatoid inflammation of the clinical observation showed that thymosin on the efficacy of RA is still satisfied .Total reports are as follows: 1 Materials and Methods 1.1 Clinical data according to the American College of Rheumatology diagnostic criteria in 1987. From 1995 In August, 92 patients were randomly selected, including 8 males and 81 females, aged from 23 years to 76 years with an average age of 19.6 ± 12.9 years and a duration of 11 months to 28 years, with an average of 5.8 ± 6.6 years. Before the treatment of thymosin Patient’s onset of x-ray staging.Ⅰstage 18 cases.Ⅱperiod 25 cases.Ⅲphase 13 cases.Ⅳ period Ⅳ.All patients were randomly divided into treatment group and control group.The treatment group 48 cases, the control group of 44 cases .Two groups Age, sex, no significant difference in the disease is comparable. Rheumatoid arthritis (RA) is a common chronic multi-joint devastating disease in the course of the disease prone to erosion and destruction of bone and joints, resulting in the loss of function , The patient’s physical and mental health caused a greater impact, at present there is no specific effect for the treatment at home and abroad.